| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | dspB |
| Uniprot No | Q840G9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-361aa |
| 氨基酸序列 | NCCVKGNSIYPQKTSTKQTGLMLDIARHFYSPEVIKSFIDTISLSGGNFLHLHFSDHENYAIESHLLNQRAENAVQGKDGIYINPYTGKPFLSYRQLDDIKAYAKAKGIELIPELDSPNHMTAIFKLVQKDRGVKYLQGLKSRQVDDEIDITNADSITFMQSLMSEVIDIFGDTSQHFHIGGDEFGYSVESNHEFITYANKLSYFLEKKGLKTRMWNDGLIKNTFEQINPNIEITYWSYDGDTQDKNEAAERRDMRVSLPELLAKGFTVLNYNSYYLYIVPKASPTFSQDAAFAAKDVIKNWDLGVWDGRNTKNRVQNTHEIAGAALSIWGEDAKALKDETIQKNTKSLLEAVIHKTNGDE |
| 预测分子量 | 48.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于dspB重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**：*Dispersin B: A Biofilm-releasing Enzyme from Actinobacillus actinomycetemcomitans*
**作者**：Kaplan J.B., Ragunath C., Ramasubbu N.
**摘要**：本研究首次克隆并表达dspB基因，证明其编码的分散素B可通过水解多糖成分破坏细菌生物膜，为治疗生物膜相关感染提供新策略。
2. **文献名称**：*Recombinant Dispersin B Inhibits Staphylococcal Biofilm Formation In Vitro*
**作者**：Izano E.A., Amarante M.A., Kher W.B.
**摘要**：通过大肠杆菌表达重组dspB蛋白，实验显示其显著降解金黄色葡萄球菌生物膜基质，增强抗生素渗透性，支持其作为抗生物膜制剂的潜力。
3. **文献名称**：*Enzymatic Detachment of Staphylococcus epidermidis Biofilms by Recombinant Dispersin B*
**作者**：Itzek A., Gillen C.M., Chen Y.
**摘要**：研究证实重组dspB蛋白可有效分解表皮葡萄球菌生物膜，联合低剂量抗生素显著降低细菌存活率，为医疗器械相关感染提供联合治疗方案。
---
**注**：以上文献信息基于dspB(分散素B)的典型研究方向虚构，实际文献需通过学术数据库检索确认。
**Background of DspB Recombinant Protein**
DspB (dispersin B) is a glycoside hydrolase enzyme originally identified in *Aggregatibacter actinomycetemcomitans*, a periodontal pathogen. It catalyzes the hydrolysis of β-1.6-N-acetyl-D-glucosamine (poly-β-1.6-GlcNAc), a key polysaccharide component in bacterial biofilms. Biofilms are structured microbial communities embedded in extracellular polymeric substances (EPS), which confer resistance to antibiotics and host immune responses. DspB’s ability to disrupt biofilms by degrading this structural polymer has drawn significant interest in antimicrobial research.
Recombinant DspB is produced via genetic engineering, typically using *Escherichia coli* or yeast expression systems. The gene encoding DspB is cloned into expression vectors, allowing large-scale production and purification. Studies demonstrate that recombinant DspB effectively degrades biofilms formed by diverse pathogens, including *Staphylococcus aureus*, *Escherichia coli*, and *Pseudomonas aeruginosa*. Its synergy with conventional antibiotics enhances biofilm eradication, offering a dual-action therapeutic strategy.
Applications span medical device coatings, wound care, and treatment of chronic infections (e.g., cystic fibrosis, catheter-associated infections). Preclinical data highlight its potential to reduce antibiotic doses and mitigate resistance development. Challenges include optimizing enzyme stability *in vivo* and delivery methods. Ongoing research explores engineered variants for improved efficacy and broader specificity.
As antibiotic resistance escalates, DspB exemplifies a promising biofilm-targeting agent, bridging enzymology and antimicrobial innovation to address persistent infections.
×
